Readystate Asset Management LP Takes $375,000 Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Readystate Asset Management LP acquired a new position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 45,400 shares of the company's stock, valued at approximately $375,000. Readystate Asset Management LP owned approximately 0.74% of Aligos Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp purchased a new position in Aligos Therapeutics in the 4th quarter valued at $205,000. Wells Fargo & Company MN purchased a new stake in shares of Aligos Therapeutics during the 4th quarter worth $869,000. Golden State Wealth Management LLC boosted its position in shares of Aligos Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock worth $44,000 after purchasing an additional 2,674 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Aligos Therapeutics by 19.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company's stock worth $569,000 after purchasing an additional 2,306 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Aligos Therapeutics by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 27,253 shares of the company's stock worth $1,086,000 after purchasing an additional 3,197 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company's stock.

Aligos Therapeutics Trading Up 2.5%

Shares of Aligos Therapeutics stock traded up $0.22 during mid-day trading on Friday, hitting $9.13. 47,451 shares of the stock were exchanged, compared to its average volume of 83,365. Aligos Therapeutics, Inc. has a twelve month low of $3.76 and a twelve month high of $46.80. The stock has a market capitalization of $55.78 million, a price-to-earnings ratio of -0.52 and a beta of 2.77. The company has a 50-day simple moving average of $7.43 and a 200 day simple moving average of $12.25.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($2.11) earnings per share for the quarter, topping the consensus estimate of ($2.80) by $0.69. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.33 million. Aligos Therapeutics had a negative net margin of 1,628.75% and a positive return on equity of 14.67%. Equities research analysts forecast that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of Aligos Therapeutics in a research note on Monday, March 31st.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).